SEATTLE & AMSTERDAM, Netherlands--(BUSINESS WIRE)--June 22, 2006--Targeted Genetics Corporation (Nasdaq:TGEN - News) announced today that the principal investigator for its current clinical studies, Philip Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, presented data from a completed Phase I and ongoing Phase I/II trial of tgAAC94 in patients with inflammatory arthritis. tgAAC94 is an investigational therapeutic designed to inhibit the activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. The data support the safety and tolerability of intra-articular administration of tgAAC94 to affected joints and suggest that tgAAC94 may lead to improvements in signs and symptoms of arthritis in injected joints. Importantly, these improvements have been observed in patients with and without concurrent systemic TNF-alpha antagonist therapies. Dr. Mease presented this data at the Annual European Congress of Rheumatology, taking place in Amsterdam June 21st-24th.
